Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.44 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 2/20 | 0.39 |
| ▸ | CTSD | P07339 | 3/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30442889 | 0.88 | CACNA2D1 (0.44) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL29885722 | 0.86 | CACNA2D1 (0.42) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL29729174 | 0.84 | CACNA2D1 (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL30738235 | 0.84 | CACNA2D1 (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL30395496 | 0.84 | CACNA2D1 (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL29384067 | 0.84 | CACNA2D1 (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL30192411 | 0.84 | CACNA2D1 (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL11909491 | 0.84 | CACNA2D1 (0.46) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL31003023 | 0.84 | CACNA2D1 (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL30373955 | 0.84 | CACNA2D1 (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115427113-A | Compositions comprising activatable antibodies | 西托姆克斯治疗公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2020138370-A1 | CANCER TREATMENT PHARMACEUTICAL COMPOSITION CONTAINING CDK INHIBITOR | 大日本住友製薬株式会社 | 2020-07-02 | — | — | WO | disclosed |
| US-10077288-B2 | Hydroxystatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2018-09-18 | — | — | US | disclosed |
| US-9624264-B2 | Hydroxystatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-20170081361-A1 | HYDROXYSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| US-9528156-B2 | Method for determining the predisposition of a patient to changed biotransformation and to the development of undesired drug effects in a treatment of the patient with atrovastatin | ROBERT BOSCH GMBH (DE) | 2016-12-27 | — | — | US | disclosed |
| US-20150225451-A1 | HYDROXYSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
| US-20120107814-A1 | Method for Determining the Predisposition of a Patient to Changed Biotransformation and to the Development of Undesired Drug Effects in a Treatment of the Patient with Atrovastatin | ROBERT BOSCH GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081361-A1 | HYDROXYSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | CTSD, CTSB, CTSZ | CACNA2D1 2960/4885CACNB3 3863/4885CACNA1C 4477/4885 |
| US-10077288-B2 | Hydroxystatin derivatives for the treatment of arthrosis | CTSD, CTSB, CTSZ | CACNA2D1 2960/4885CACNB3 3863/4885CACNA1C 4477/4885 |
| US-20150225451-A1 | HYDROXYSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | CTSD, CTSB, CTSZ | CACNA2D1 2960/4885CACNB3 3863/4885CACNA1C 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.